4Basebio PLC - Heidelberg, Germany-based life sciences company - Nearly quintuples annual loss. 2021 pretax loss widens to £3.6 million from £716,000 in 2020. Revenue falls to £338,000 from £462,000 the year before. Research and development expenses grow to £1.6 million from £343,000. Administration costs rise to £1.7m from £516,000. ‘The group invested heavily during 2021,’ 4Basebio explains. 4Basebio listed on AIM in February of last year.
Company is now developing and manufacturing synthetic DNA and RNA products, it says. ‘The group’s near-term focus is the commercial supply of DNA and mRNA to partners for a range of gene therapy and vaccine applications,’ it adds. Progress made in 2021 ‘has led to our first DNA sales during 2022 and growing interest in our products,’ says Chief Executive Officer Heikki Lanckriet.
Current stock price: 500.00 pence, down 9.1% on Monday
12-month change: up 35%
Copyright 2022 Alliance News Limited. All Rights Reserved.
